292 related articles for article (PubMed ID: 28407998)
1. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.
Tuffaha HW; Mitchell A; Ward RL; Connelly L; Butler JRG; Norris S; Scuffham PA
Genet Med; 2018 Sep; 20(9):985-994. PubMed ID: 29300376
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
Moya-Alarcón C; González-Domínguez A; Simon S; Pérez-Román I; González-Martín A; Bayo-Lozano E; Sánchez-Heras AB
Clin Transl Oncol; 2019 Aug; 21(8):1076-1084. PubMed ID: 30617925
[TBL] [Abstract][Full Text] [Related]
6. BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
Kwon JS; Tinker AV; Hanley GE; Pansegrau G; Sun S; Carey MS; Schrader I
Gynecol Oncol; 2019 Mar; 152(3):459-464. PubMed ID: 30876489
[TBL] [Abstract][Full Text] [Related]
7. Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops.
Hurry M; Eccleston A; Dyer M; Hoskins P
Int J Technol Assess Health Care; 2020 Apr; 36(2):104-112. PubMed ID: 32423520
[TBL] [Abstract][Full Text] [Related]
8. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
[TBL] [Abstract][Full Text] [Related]
10. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Whole Population BRCA Genetic Screening for Cancer Prevention in Israel.
Michaan N; Leshno M; Safra T; Sonnenblick A; Laskov I; Grisaru D
Cancer Prev Res (Phila); 2021 Apr; 14(4):455-462. PubMed ID: 33355193
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
[TBL] [Abstract][Full Text] [Related]
13. Expanding the criteria for BRCA mutation testing in breast cancer survivors.
Kwon JS; Gutierrez-Barrera AM; Young D; Sun CC; Daniels MS; Lu KH; Arun B
J Clin Oncol; 2010 Sep; 28(27):4214-20. PubMed ID: 20733129
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
Manchanda R; Patel S; Antoniou AC; Levy-Lahad E; Turnbull C; Evans DG; Hopper JL; Macinnis RJ; Menon U; Jacobs I; Legood R
Am J Obstet Gynecol; 2017 Nov; 217(5):578.e1-578.e12. PubMed ID: 28690137
[TBL] [Abstract][Full Text] [Related]
15. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
[TBL] [Abstract][Full Text] [Related]
17. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
18. Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.
D'Andrea E; Marzuillo C; De Vito C; Di Marco M; Pitini E; Vacchio MR; Villari P
Genet Med; 2016 Dec; 18(12):1171-1180. PubMed ID: 27906166
[TBL] [Abstract][Full Text] [Related]
19. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
[TBL] [Abstract][Full Text] [Related]
20. Preventing future cancers by testing women with ovarian cancer for BRCA mutations.
Kwon JS; Daniels MS; Sun CC; Lu KH
J Clin Oncol; 2010 Feb; 28(4):675-82. PubMed ID: 19841329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
